Management of Symptomatic Advanced Pancreatic Adenocarcinoma: Urgence Pancreas - A Prospective A.R.CA.D Cohort Study
This study assessed the feasibility and effects of an early integrative supportive care program in patient with advanced pancreatic adenocarcinoma (aPDAC).
• Pathologically confirmed or highly suspected aPDAC defined as a pancreatic mass on imaging, suspected distant metastases, no features suggestive of a neuroendocrine tumor, and/or clinico-biological abnormalities compatible with the diagnosis of aPDAC,
• Age ≥ 18 years,
• Patients with ECOG PS ≥ 2 and clinico-biological features precluding initial therapeutic clinical trial and/or treatment with FOLFIRINOX or gemcitabine + nab-paclitaxel,
• No prior history of cancer, except: in situ breast, cervix cancer, or basal cell carcinoma and/or complete remission for more than 3 years from another cancer.
• Registration in France with the French National Health Care System (CMU included)
• Patient able to comply with study protocol requirements in the view of the investigator,
• Before patient registration, written informed consent must be obtained according to ICH/GCP and national/local regulations,
• Patients requiring at least two components of the integrative care program (pain management, nutritional management, pathological assessment or imaging, and endoscopy/stent).